Flocare

Quick links to important sections

Flocare

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flocare

Flocare is a pharmaceutical product primarily defined by its active ingredient, Fluticasone Propionate (INN), which is a synthetic glucocorticoid—a type of potent anti-inflammatory agent. The medication is classified as a single-ingredient product (monotherapy) and is specially formulated for localized application, ensuring its activity is concentrated where needed.


Quick Facts

Property Description
Active ingredient Fluticasone Propionate (INN)
Form Metered-Dose Nasal Spray (Suspension)
Pharmacological class Topical Corticosteroid / Glucocorticoid
General purpose Anti-inflammatory action on nasal lining
Origin Synthetic

Flocare: A Definitional Overview of its Active Ingredient

The active component in Flocare is Fluticasone Propionate, a compound classified as a potent Topical Corticosteroid that falls under the larger pharmacological class of Glucocorticoids. This synthetic compound is widely recognized in pharmacological studies for its high binding affinity to receptors, which supports its efficacy in managing nasal inflammation. Flocare may be encountered in various international markets, packaged as an over-the-counter (OTC) medicine or a prescription product, depending on the specific country's regulatory status, though its chemical nature remains consistent.

Form, Delivery Method, and Composition of Flocare

Flocare is prepared as a specialized Metered-Dose Nasal Spray (Suspension), which is the designated dosage form for Intranasal administration. This delivery method is crucial for efficiently depositing the medicine directly onto the nasal lining, the intended site of action. This type of nasal formulation is clinically recognized for its ability to decrease swelling and inflammation directly where symptoms occur. The core composition consists of the active ingredient, Fluticasone Propionate, suspended within an aqueous microcrystalline base/vehicle that ensures consistent and targeted application of the drug to the nasal mucosa.

General Purpose of this Glucocorticoid Nasal Spray

The general therapeutic purpose of Flocare's glucocorticoid action is to provide comprehensive control of the underlying inflammation within the nasal lining. By exerting this powerful anti-inflammatory action directly at the site of application, the medication effectively addresses the tissue swelling and irritation (known as mucosal edema). This function results in the significant relief of symptoms associated with nasal inflammation, ultimately restoring comfort and improving airflow within the nasal passages.

Regulatory References

  1. U.S. National Library of Medicine
  2. MedlinePlus - NIH

What side effects are possible with Flocare?

The official safety profile for Flocare, which contains Fluticasone Propionate, is documented based on frequency classifications and system-organ class groupings from regulatory authorities such as the FDA and EMA. The most common adverse reactions are generally localized to the application site.

Adverse Reaction Classification

Classification Examples of Officially Documented Adverse Reactions
Very Common Epistaxis (nosebleeds) in some documented uses.
Common Headache; nasal irritation, dryness, or burning; pharyngeal irritation (sore throat); changes in taste or smell (dysgeusia/dysosmia).
Very Rare Systemic hypersensitivity reactions, including anaphylaxis, angioedema, and bronchospasm; nasal septal perforation; ocular effects such as cataracts and glaucoma.

Serious Adverse Reactions and Safety Considerations

Serious adverse events are classified as very rare and relate primarily to the drug's corticosteroid nature.

  • Systemic Effects: Adrenal suppression (HPA axis suppression) and features of hypercorticism are documented potential risks, particularly associated with prolonged use or at high doses.
  • Ocular Effects: The development of Cataracts or Glaucoma is an officially noted risk tied to long-term exposure to intranasal corticosteroids.
  • Pediatric Population: Official labels note that use in children may cause a reduction in growth velocity, a factor that requires monitoring during extended administration.
  • Safety Restrictions: Caution is advised in patients with certain conditions, including active or quiescent tuberculosis, untreated systemic infections, or recent nasal trauma/surgery, due to the potential for impaired wound healing or worsening of infections.

The overall safety profile is structured to distinguish between frequent, localized events and the rare, but significant, potential for systemic corticosteroid adverse effects documented over long-term use.

Overdose and Emergency Response

The official regulatory profile for Fluticasone Propionate nasal spray, the active ingredient in Flocare, distinguishes between acute overdose and the risks associated with prolonged, excessive use. Due to the medication’s low systemic absorption when administered intranasally, an acute overdose is generally not expected to produce life-threatening symptoms and often requires only supportive observation.

Documented Overdose Manifestations

The primary documented concern associated with prolonged administration of doses higher than officially recommended is the potential for systemic corticosteroid effects. Manifestations resulting from such overuse include Hypercorticism and Suppression of HPA (Hypothalamic-Pituitary-Adrenal) function, commonly referred to as Adrenal Suppression. This serious outcome requires careful medical management involving the gradual discontinuation of the dosage under the direction of a healthcare professional, as no specific antidote is known.

When to Seek Urgent Medical Help

Official regulatory statements mandate that individuals seek medical help or contact a Poison Control Center right away in the event of any suspected overdose. Population-specific considerations are noted in official labeling: there is a risk of suppression of linear growth rate in children with chronic, high-dose exposure, and an increased systemic risk for patients with severe liver disease.

Therapeutic Uses of Flocare

What Flocare Treats: Main Uses and Benefits

Targeting Wide-Ranging Bacterial Discomfort

Flocare is applied across domains where additional symptomatic support is needed and may be part of symptomatic management in situations involving certain distressing symptoms. This medicine is relevant in contexts marked by increased discomfort or tension, and supports the patient by helping ease the overall symptom burden. It is commonly used for conditions involving symptoms related to systemic imbalance, inflammatory processes, and organ-specific functional stress.


Key Areas and Patient Benefits

The medication helps address symptom clusters that may become intense or disruptive during acute infectious episodes. It is often used when symptoms intensify and supportive relief is needed, assisting with maintaining functional stability when symptoms interfere with routine activities. The medication offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

“Applied in scenarios where additional management of discomfort is required.”


Quick Fact

Quick Fact: Assistance with symptoms related to physical discomfort

Regulatory References

  1. NIH MedlinePlus overview of Ofloxacin

Eligibility and Restrictions for Use

Eligibility Scope

Classification Population Status
Populations for whom use is allowed Adults, adolescents, and children aged 4 years and older. Established
Populations for whom use is contraindicated Patients with known hypersensitivity (allergy) to Fluticasone Propionate or any other ingredient in the product. Prohibited
Populations for whom use is not recommended Children younger than 4 years of age. Not Established

Eligibility-Related Restrictions

Restriction Context Population Constraint Status
Local Nasal Integrity Individuals with recent nasal surgery, nasal trauma, or nasal ulcers. Avoid Use
Infection/Comorbidity Patients with certain existing infections (e.g., tuberculosis), a history of glaucoma or cataracts, or moderate to severe hepatic impairment. Use with Caution
Reproductive Status Individuals who are pregnant or breastfeeding. Conditional Use

Connection to the Overall Eligibility Profile

Regulatory documents strictly define eligibility by setting absolute contraindications based on allergy and establishing a minimum approved age of 4 years. For patient groups with impaired local nasal integrity, certain existing infections, or during pregnancy/lactation, the label mandates conditional use or cautionary monitoring to define the boundaries of eligibility.

What should I know about interactions with other medicines?

Flocare Interactions with other medicines and products

Flocare has documented interactions with other medicinal products and substances, which are categorized based on their mechanism and clinical significance. The primary mechanisms involve the drug's metabolism and its effects on the central nervous system (CNS) and cardiac rhythm.

Interacting Product Category Interaction Mechanism and Constraint
QT-Prolonging Agents Co-administration may result in additive effects on the QT interval, requiring caution and monitoring.
Antacids and Mineral Supplements Products containing calcium, magnesium, iron, or zinc should be spaced out from Flocare administration (typically by at least two hours) as they can significantly reduce the absorption and effectiveness of Flocare.
Medicines affecting Seizure Threshold Co-administration with certain non-steroidal anti-inflammatory drugs (NSAIDs) or theophylline may increase the risk of CNS excitation and seizures.

Officially listed interacting medicines that must be used with caution include warfarin, due to potential effects on its blood-thinning activity, requiring strict monitoring of INR levels. Alcohol should be avoided as it can increase the risk of certain adverse central nervous system effects associated with Flocare. The interaction profile is structured to inform necessary adjustments, such as timing separation or increased patient monitoring, when co-administration cannot be avoided.

Mechanism of Action

Genomic Suppression via the Glucocorticoid Receptor

The drug's effect is driven exclusively by its anti-inflammatory action at the cellular level. It functions as a single-ingredient topical glucocorticoid, engaging specific genomic pathways to modulate the localized immune response. The drug acts as a full agonist at the Glucocorticoid Receptor (GR), a nuclear target within nasal mucosal cells. The drug-receptor complex then translocates to the nucleus where it performs transrepression, functionally inhibiting key pro-inflammatory transcription factors like NF-kappa B. This action suppresses the genetic signaling responsible for creating inflammatory proteins, representing a form of pathway modulation.

Inhibition of Mediator Synthesis and Cellular Influx

By suppressing pro-inflammatory gene expression, Flocare halts the creation of inflammatory mediators, including certain cytokines and chemicals in the Arachidonic Acid Cascade (like Prostaglandins and Leukotrienes). This cascade-level inhibition, coupled with the drug’s action to reduce the infiltration and activity of immune cells like eosinophils, promotes local vasoconstriction and decreases microvascular permeability.

Causal Link to Physiological Consequence

The resulting physiological consequence of halting inflammatory chemical production and stabilizing local blood vessels is a reduction in mucosal edema (swelling) and tissue volume. Because this mechanism relies on changing the cell's genetic output, the full effect emerges gradually over hours to days.

Dosage and Administration Information

How to Use Flocare

Flocare, which contains the active ingredient Fluticasone Propionate (50 mcg per spray), is a Metered-Dose Nasal Spray that is restricted to the intranasal route of administration. The correct usage protocol dictates preparation and adherence to specific dosing schedules.


Official Dosing and Frequency

Administration typically follows a pattern of an initial dose, which is then reduced for maintenance, based on the principle of using the lowest effective amount.

Population Starting Daily Dose Administration Frequency
Adults 200 mcg (2 sprays in each nostril) Once daily or Divided Twice Daily
Pediatric (Ages 4 and older) 100 mcg (1 spray in each nostril) Once daily

For adults, the total daily dose should not exceed 200 mcg. Once control of symptoms is achieved, the dosage is formally titrated downward to the minimal amount (often 100 mcg per day) that sustains the desired effect.


Administration Requirements

Proper use of the device requires several procedural steps. The nasal spray must be primed prior to its first use, or if the device has not been used for a specific duration (typically seven days or more). The bottle should also be gently shaken before each daily administration to ensure the suspension is properly mixed. If a dose is missed, the protocol is to skip the missed dose and resume the regular schedule; a dose should not be doubled to compensate.

Recent Clinical Evidence

Flocare is a product name associated with a range of enteral feeding equipment, including pumps, tubes, and accessories, used for nutritional support. The evidence surrounding Flocare is primarily centered on its role as a medical device in clinical procedures and its application in different patient populations requiring tube feeding.

Clinical Applications and Observations

Clinical studies have explored the effectiveness of various techniques and adjunctive therapies used with nasoenteric tubes, such as those in the Flocare range, particularly in critically ill patients. Key findings from randomized controlled trials (RCTs) include:

  • Tube Placement Success: Research has evaluated methods to improve the success rate of achieving post-pyloric tube placement (i.e., placement beyond the stomach). For example, one multicenter RCT found that the use of prokinetic agents (such as metoclopramide or domperidone) significantly increased the success rate of achieving post-pyloric tube tip positioning within 24 hours, compared to a control group.
  • Migration Distance: This trial also observed that the average tube migration distance was significantly greater in groups receiving these agents, supporting the use of adjunctive therapies to aid in positioning the feeding tube for optimal nutrient delivery.
  • Nutritional Support in Specific Conditions: Other research focuses on the overall strategy of enteral nutrition (EN) delivered via systems like Flocare. For instance, studies in patients undergoing complex procedures like allogeneic hematopoietic stem cell transplantation (AHSCT) have investigated whether EN affects outcomes compared to parenteral nutrition (PN), although more randomized evidence is continually sought to define the optimal support type.

Safety and Device Compliance

The Flocare line of equipment is compliant with standards established for enteral devices. As a medical device, safety analysis involves monitoring device performance. Previous reports have focused on operational aspects, such as the potential for 'air in line' alarm issues when the feeding pump is used with certain types of mixed or reconstituted powdered tube feeds. Users are advised to adhere strictly to the updated instructions for use to mitigate such operational risks.

Key Studies & References

  1. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (Clinical Guideline CG32) - NICE
  2. Flocare Infinity Pump Alarms (English) - YouTube (Used for reference on common operational issues/alarms)
  3. TROUBLESHOOTING & PUMP ALARMS STEP BY STEP GUIDE (Flocare Infinity III) - Nutricia Homeward

Frequently Asked Questions (FAQ)

Common questions about Flocare (FAQ)


Q: How quickly should Flocare start showing an effect?

A: Studies indicate that initial symptom relief may begin within 12 hours of the first dose. The full therapeutic effect is generally achieved after using Flocare for one to two weeks consistently. This gradual onset is a common feature, as the medication works by reducing inflammation over time.


Q: Is Flocare safe for general long-term use?

A: Official product information states that long-term continuous use may rarely be associated with certain systemic effects. These potential risks include eye problems, such as cataracts or glaucoma, and changes in bone mineral density. Official labels note the importance of regular health monitoring for individuals using the medication for extended periods.


Q: Does Flocare interact with common pain relievers like ibuprofen or acetaminophen?

A: According to official drug interaction profiles, there is no identified interaction between Flocare and the common pain reliever acetaminophen (the active ingredient in Tylenol). Information about other specific pain relievers can be found in the dedicated Interactions section.


Q: What is the available research evidence that Flocare is effective?

A: Clinical studies reviewed by regulatory bodies indicate that Flocare is significantly more effective than a placebo in reducing the nasal symptoms of allergic rhinitis. The evidence supports its use for both seasonal and perennial (year-round) allergies.


Q: Are there any specific vitamins or supplements that are known to interact with Flocare?

A: Regulatory documents advise caution regarding the combination of Flocare with certain herbal remedies and supplements, as these products are not typically tested for drug interactions. Specific vitamins, such as Vitamin C or D3, are noted in interaction checkers as having potential interactions.


Q: Can Flocare be taken at the same time as my other regular medications?

A: Official labeling indicates that Flocare is known to interact with a few specific categories of medicines that affect its metabolism. These include certain strong medicines for HIV and some fungal infection treatments. You can find more detail on known risks in the dedicated Interactions section.


Q: What is the main thing Flocare is used to treat?

A: According to the official regulatory documents, Flocare is indicated for managing the nasal symptoms associated with both seasonal (e.g., hay fever) and perennial (year-round) allergic rhinitis. Some formulations are also approved for symptoms related to chronic sinus issues.


Q: Is it normal to feel slightly dizzy or lightheaded when first starting Flocare?

A: Official product information indicates that dizziness or lightheadedness is not a common side effect. However, while rare, this feeling may be noted in regulatory warnings as a potential sign of a serious, though reversible, adrenal gland disorder associated with systemic steroid effects.


Q: Has Flocare been approved by major regulatory bodies like the FDA or EMA?

A: The active ingredient in Flocare, fluticasone propionate, is an officially approved drug product available in jurisdictions governed by the FDA (U.S.), EMA (Europe), and other major regulatory bodies. These agencies monitor its quality and safety profile.


Q: Can Flocare affect fertility or is it safe during pregnancy?

A: Based on available data, the medication is generally considered acceptable for use during pregnancy and breastfeeding. Furthermore, there is no evidence in regulatory documents suggesting that Flocare reduces fertility.


Q: Is Flocare safe for people over the age of 65?

A: Studies have not demonstrated any age-specific restrictions that limit the usefulness of the medication in older adults. However, a general caution is noted that elderly patients may be more likely to have age-related impairment of organ function.


Q: Does taking Flocare cause any changes in body weight?

A: Weight change is not a common side effect. However, regulatory warnings note that rare cases of systemic side effects, specifically an adrenal gland disorder known as hypercorticism, may include symptoms such as unusual tiredness, weakness, and changes in body weight.


Q: What is the usual total duration of treatment recommended for Flocare?

A: Official labeling notes duration limits for over-the-counter (OTC) use. Adults should limit use to six months and children (ages 4–11 years) to two months. Official instructions state that medical consultation is appropriate if symptoms persist beyond these general expectations.


Q: Does Flocare have any effect on blood sugar levels or diabetes?

A: As a corticosteroid, prolonged use or very high doses may rarely increase the risk of systemic effects. These systemic effects can include signs of hypercorticism, a condition that may potentially affect blood sugar regulation.


Q: Does Flocare interact with common cold or allergy medicines?

A: Clinical experience and studies indicate that Flocare can generally be used with certain common allergy medicines, such as non-sedating antihistamines (e.g., cetirizine). The interaction profile of the medication is considered minor with these drugs.


Q: How long does the main benefit of a single dose of Flocare last?

A: The medication is designed for convenient and consistent daily use. According to the official dosing and administration instructions, a single daily dose is formulated to provide 24-hour relief of symptoms.


Q: Is Flocare a generic or a brand-name drug?

A: Flocare is a product name, but its active ingredient is called fluticasone propionate. This active ingredient is the generic chemical name and is sold under various brand names depending on the manufacturer and region.


Q: Does Flocare contain any common allergens like lactose or gluten?

A: Official labeling lists all inactive ingredients. The product is widely noted in regulatory documents and patient information to be free of common allergens such as lactose and gluten.


Q: What is the difference between Flocare and its active ingredient?

A: Flocare is the name of the finished product, whereas fluticasone propionate is the active ingredient. The active ingredient is the chemical substance responsible for providing the therapeutic anti-inflammatory effect.


Q: Why is Flocare sometimes described as a 'maintenance' drug?

A: The medication is recommended for continuous, daily use throughout the entire allergy season or for long-term perennial symptoms, rather than for use as needed. This pattern of regular, sustained administration is characteristic of a maintenance therapy.


Q: Are there any known issues with stopping Flocare suddenly?

A: Regulatory warnings note that sudden discontinuation is a caution when an individual is switching from other strong oral corticosteroids. This is due to the potential risk of systemic withdrawal effects.


Q: Does Flocare have a 'black box warning' mentioned in official documents?

A: Official product information confirms that the U.S. FDA-approved labeling for the product does not currently contain a Black Box Warning.


Q: Are there any common misuses of Flocare that I should be aware of?

A: Regulatory documents emphasize that the product is not intended for use in unapproved conditions like the common cold or in children younger than the approved age range.


Q: Does Flocare expire quickly after opening the package?

A: Official product labeling provides disposal guidance, noting that unused product should be discarded after a specified number of sprays have been dispensed or by the expiration date printed on the package.

How should Flocare be stored and disposed of?

How to Store and Dispose of Flocare?

The storage and disposal instructions for Fluticasone Propionate Nasal Spray (Flocare) are governed by strict regulatory rules to maintain product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at room temperature (4 C to 30 C / 39 F to 86 F) and keep from freezing.
Protection Store away from excess heat, moisture, and direct light; keep the container tightly closed.
Handling The suspension must be shaken gently before each use to ensure consistent dosing.
Safety The medication must be kept out of the sight and reach of children.

Disposal

The nasal spray unit must be discarded after the marked number of metered sprays (typically 120 actuations) has been used, even if liquid remains. Disposal of used or expired product must be done according to local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Flocare found in:

A-Z Index: